Highlights From the 63rd ASH Annual Meeting
Follow-up of More Than 5 Years in a Cohort of Patients with Hemophilia B Treated With Fidanacogene Elaparvovec Adeno-Associated Virus Gene Therapy
Ben J. Samelson-Jones, MD, PhD1, Spencer K. Sullivan, MD2, John E.J. Rasko, BSc (Med), MBBS (Hons), PhD, MAICD, FFSc (RCPA), FRCPA, FRACP, FAHMS3*, Adam Giermasz, MD, PhD4, Lindsey A. George, MD1,5, Jonathan M. Ducore, MD, MPH6, Jerome M. Teitel, MD, FRCPC7, Catherine E. McGuinn, MD8, Amanda O'Brien9*, Ian Winburn, MBBS, PhD, MRCS10*, Lynne M Smith, MBA9*, Amit Chhabra, MBBS, MPH11, and Jeremy Rupon, MD9
1The Children's Hospital of Philadelphia, Philadelphia, PA
2Mississippi Center for Advanced Medicine, Madison, MS
3Cell & Molecular Therapies, Royal Prince Alfred Hospital, SLHD, Australia
4University of California Davis, Sacramento, CA
5Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
6Hemophilia Treatment Center, UC Davis, Sacramento, CA
7University of Toronto, St. Michael's Hospital, Toronto, Canada
8Columbia University, New York, NY
9Pfizer Inc, Collegeville, PA
10Pfizer Ltd, Tadworth, Surrey, United Kingdom
11Pfizer Inc, New York, NY